Biotech Bid Up Following First Patient Dosage

Biotech Bid Up Following First Patient Dosage

A Boston-based biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119,...

To read the full story on AllPennyStocks.com, click here.

Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Feb 2023 to Mar 2023

Click Here for more Aprea Therapeutics Charts.

Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Mar 2022 to Mar 2023

Click Here for more Aprea Therapeutics Charts.

Aprea Therapeutics Inc News

Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
Thursday 16 March 2023 (1 week ago) • GlobeNewswire Inc.

Current Report Filing (8-k)
Monday 13 March 2023 (2 weeks ago) • Edgar (US Regulatory)

Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
Wednesday 8 March 2023 (3 weeks ago) • GlobeNewswire Inc.

Statement of Ownership (sc 13g)
Friday 3 March 2023 (3 weeks ago) • Edgar (US Regulatory)

Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Thursday 2 March 2023 (3 weeks ago) • GlobeNewswire Inc.

Statement of Changes in Beneficial Ownership (4)
Tuesday 28 February 2023 (4 weeks ago) • Edgar (US Regulatory)

Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
Tuesday 28 February 2023 (4 weeks ago) • GlobeNewswire Inc.

Current Report Filing (8-k)
Saturday 25 February 2023 (4 weeks ago) • Edgar (US Regulatory)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
Saturday 25 February 2023 (4 weeks ago) • Edgar (US Regulatory)

Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
Thursday 23 February 2023 (1 month ago) • GlobeNewswire Inc.

Aprea Therapeutics Announces Proposed Public Offering of Common Stock
Thursday 23 February 2023 (1 month ago) • GlobeNewswire Inc.

Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
Thursday 16 February 2023 (1 month ago) • GlobeNewswire Inc.

More Aprea Therapeutics Inc News Articles

Your Recent History

FX

EURAUD

Euro vs Au..

FX

USDAUD

US Dollar ..

ASX

WPL

Woodside

NASDAQ

AAPL

Apple

ASX

BHP

BHP Bilito..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

Log in to ADVFN

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V:au D:20230325 08:24:29